Unnamed: 0,title,date,stock,sentiment
1389902.0,"XOMA Q1 EPS $(0.490) Down From $0.210 YoY, Sales $800.000K Down From $8.131M YoY",2020-05-05 07:39:00-04:00,XOMA,neutral
1389903.0,"XOMA Q4 EPS $(0.49) Down From $(0.35) YoY, Sales $423K Down From $1.685M YoY",2020-03-10 07:39:00-04:00,XOMA,neutral
1389904.0,Zydus and XOMA Earlier Announce IL-2-Based Immuno-Oncology Therapy Licensing Agreement,2020-03-09 10:00:00-04:00,XOMA,positive
1389905.0,146 Biotechnology Stocks Moving In Thursday's Session,2020-01-23 12:47:00-05:00,XOMA,neutral
1389906.0,"The Daily Biotech Pulse: Flexion Receives FDA Nod For Zilretta Label Expansion, Astellas Goes Shopping",2019-12-27 07:59:00-05:00,XOMA,neutral
1389907.0,"The Daily Biotech Pulse: Qiagen Opts To Stay Solo Following Strategic Review, Spectrum Slumps On Negative Data, Microbot Medical To Offer Shares",2019-12-26 07:55:00-05:00,XOMA,negative
1389908.0,"The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict",2019-12-24 07:24:00-05:00,XOMA,negative
1389909.0,78 Biggest Movers From Yesterday,2019-12-24 04:32:00-05:00,XOMA,neutral
1389910.0,"Mark N. Lampert Raises Stake in Xoma to 27.1% as of December 18, 2019 vs 20.4%",2019-12-23 06:08:00-05:00,XOMA,neutral
1389911.0,"The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data",2019-11-20 07:25:00-05:00,XOMA,positive
1389912.0,"XOMA Corp In 8-K Says On Nov. 19, Co. Entered Investment Agreement With Affiliates Of BVF Partners I",2019-11-20 06:16:00-05:00,XOMA,positive
1389913.0,XOMA Says on Nov 19 Co Entered Into an Investment Agreement With Certain Affiliates of BVF Partners L.P.,2019-11-20 06:14:00-05:00,XOMA,positive
1389914.0,XOMA Reports $22M Rights Offering,2019-11-19 16:31:00-05:00,XOMA,neutral
1389915.0,Stocks That Hit 52-Week Highs On Tuesday,2019-11-19 10:21:00-05:00,XOMA,neutral
1389916.0,"The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout",2019-11-19 07:56:00-05:00,XOMA,neutral
1389917.0,Stocks That Hit 52-Week Highs On Friday,2019-11-15 10:14:00-05:00,XOMA,neutral
1389918.0,"The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval",2019-11-15 07:08:00-05:00,XOMA,negative
1389919.0,Stocks That Hit 52-Week Highs On Thursday,2019-11-14 10:09:00-05:00,XOMA,neutral
1389920.0,"The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing",2019-11-14 08:07:00-05:00,XOMA,positive
1389921.0,"The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher",2019-11-13 07:10:00-05:00,XOMA,neutral
1389922.0,"The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat",2019-11-12 07:20:00-05:00,XOMA,neutral
1389923.0,Stocks That Hit 52-Week Highs On Friday,2019-11-08 10:30:00-05:00,XOMA,neutral
1389924.0,"The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut",2019-11-08 08:14:00-05:00,XOMA,neutral
1389925.0,"XOMA Q3 EPS $0.2 Up From $(0.55) YoY, Sales $8.9M Up From $896K YoY",2019-11-05 08:20:00-05:00,XOMA,neutral
1389926.0,"The Daily Biotech Pulse: ESMO Conference Gets Underway, J&J's Darzalex Snags Another Approval, Kaleido Biosciences CFO To Leave",2019-09-27 07:56:00-04:00,XOMA,positive
1389927.0,XOMA Acquires Royalty Interest Position in Six Clinical-Stage Assets For $10M,2019-09-26 16:08:00-04:00,XOMA,positive
1389928.0,"The Daily Biotech Pulse: China Biologics Receives Buyout Offer, Provention Bio Offering, Exagen IPO",2019-09-19 07:39:00-04:00,XOMA,neutral
1389929.0,"The Daily Biotech Pulse: NewLink Genetics Rallies, Breakthrough Designation For Roche, IGM Biosciences Debuts",2019-09-18 07:39:00-04:00,XOMA,neutral
1389930.0,"XOMA Reports J&J's Janssen Has Elected to Accelerate Base Annual License Fee Obligation, Will Make 1-Time $2.5M Payment To Co.",2019-08-12 07:34:00-04:00,XOMA,neutral
1389931.0,"XOMA Q2 EPS $(0.47) Beats $(0.55) Estimate, Sales $962K Beat $820K Estimate",2019-08-06 07:33:00-04:00,XOMA,neutral
1389932.0,"XOMA Reports First Patient Dosed Gevokizumab in Collaborator Clinical Study in Metastatic Colorectal Cancer, Gastroesophageal Cancer, and Renal Cell Carcinoma",2019-06-13 06:52:00-04:00,XOMA,negative
1389933.0,"XOMA Q1 EPS $0.21 Up From $(0.46) YoY, Sales $8.131M Beat $4.22M Estimate",2019-05-06 18:13:00-04:00,XOMA,neutral
1389934.0,XOMA Reports Purchase Of Royalty Rights To 5 Hematology Candidates From Aronora For $6M In Initial Payment Plus Up To $3M Upon Fulfillment Of Certain Conditions,2019-04-08 06:01:00-04:00,XOMA,positive
1389935.0,"XOMA Q4 EPS $(0.35) Beats $(0.49) Estimate, Sales $1.685M Beat $1.13M Estimate",2019-03-07 07:11:00-05:00,XOMA,neutral
1389936.0,58 Biggest Movers From Yesterday,2019-02-14 05:35:00-05:00,XOMA,neutral
1389937.0,36 Biggest Movers From Friday,2018-11-26 05:26:00-05:00,XOMA,neutral
1389938.0,"Xoma 10%+ Owner Lamper Buys 31,990 @ Avg Price: $13.48",2018-11-19 10:30:00-05:00,XOMA,neutral
1389939.0,XOMA Prices $20M Rights Offering At $13/Share,2018-11-07 07:12:00-05:00,XOMA,neutral
1389940.0,"XOMA Corporation Q3 EPS $(0.55) Misses $(0.15) Estimate, Sales $896K Miss $3.92M Estimate",2018-11-07 07:12:00-05:00,XOMA,negative
1389941.0,"The Daily Biotech Pulse: Gilead's Q2, Syndax Breast Cancer Drug Setback, Synergy Pharma On Brink Of Default",2018-10-26 08:17:00-04:00,XOMA,negative
1389942.0,58 Biggest Movers From Friday,2018-10-22 05:11:00-04:00,XOMA,neutral
1389943.0,42 Stocks Moving In Friday's Mid-Day Session,2018-10-19 12:53:00-04:00,XOMA,neutral
1389944.0,"The Daily Biotech Pulse: Novartis Positive Liver Drug Trials, Krytstal Prices Offering, LogicBio To Debut",2018-10-19 08:28:00-04:00,XOMA,positive
1389945.0,50 Biggest Movers From Yesterday,2018-10-19 05:50:00-04:00,XOMA,neutral
1389946.0,"The Daily Biotech Pulse: Clinical Hold Lifted Off Crispr's Gene-Edited Therapy, Endra To Offer Shares",2018-10-11 07:39:00-04:00,XOMA,positive
1389947.0,41 Biggest Movers From Yesterday,2018-09-27 05:01:00-04:00,XOMA,neutral
1389948.0,"XOMA Reports Purchase Of Royalty Interest Position From Agenus On 7 Assets Being Developed By Merck, Incyte For $15M",2018-09-21 07:00:00-04:00,XOMA,positive
1389949.0,26 Stocks Moving In Tuesday's Pre-Market Session,2018-09-04 08:01:00-04:00,XOMA,neutral
1389950.0,50 Biggest Movers From Friday,2018-08-20 05:33:00-04:00,XOMA,neutral
1389951.0,58 Biggest Movers From Yesterday,2018-08-15 05:02:00-04:00,XOMA,neutral
1389952.0,55 Biggest Movers From Yesterday,2018-08-14 04:50:00-04:00,XOMA,neutral
1389953.0,85 Biggest Movers From Yesterday,2018-08-09 05:15:00-04:00,XOMA,neutral
1389954.0,68 Stocks Moving In Wednesday's Mid-Day Session,2018-08-08 12:30:00-04:00,XOMA,neutral
1389955.0,"XOMA Q2 EPS $(0.23) Misses $(0.20) Estimate, Sales $2.255M Miss $3.24M Estimate",2018-08-07 16:44:00-04:00,XOMA,negative
1389956.0,58 Biggest Movers From Yesterday,2018-06-01 04:47:00-04:00,XOMA,neutral
1389957.0,"XOMA Q1 EPS $(0.46) Beats $(0.53) Estimate, Sales $463K Miss $2.72M Estimate",2018-05-09 17:34:00-04:00,XOMA,negative
1389958.0,56 Biggest Movers From Yesterday,2018-03-09 04:51:00-05:00,XOMA,neutral
1389959.0,45 Stocks Moving In Thursday's Mid-Day Session,2018-03-08 12:31:00-05:00,XOMA,neutral
1389960.0,XOMA S-3 Shows Registration For $300M Mixed Securities Shelf Offering,2018-03-07 16:46:00-05:00,XOMA,positive
1389961.0,"XOMA Reports Q4 EPS $(0.16) vs $(0.35) Est., Sales $5.357M vs $3M Est.",2018-03-07 16:06:00-05:00,XOMA,neutral
1389962.0,42 Biggest Movers From Yesterday,2018-02-28 04:49:00-05:00,XOMA,neutral
1389963.0,33 Biggest Movers From Yesterday,2018-02-06 05:09:00-05:00,XOMA,neutral
1389964.0,31 Stocks Moving In Monday's Mid-Day Session,2018-02-05 12:43:00-05:00,XOMA,neutral
1389965.0,"XOMA Licenses its XOMA 358 to Rezolute, XOMA to Receive $18M in Cash and Stock",2017-12-07 08:39:00-05:00,XOMA,neutral
1389966.0,4 Biotech Stocks To Better Your Financial Health This Winter,2017-12-04 12:25:00-05:00,XOMA,positive
1389967.0,45 Biggest Movers From Friday,2017-11-20 05:09:00-05:00,XOMA,neutral
1389968.0,56 Biggest Movers From Yesterday,2017-11-08 04:40:00-05:00,XOMA,neutral
1389969.0,45 Stocks Moving In Tuesday's Mid-Day Session,2017-11-07 12:41:00-05:00,XOMA,neutral
1389970.0,40 Stocks Moving In Tuesday's Pre-Market Session,2017-11-07 08:07:00-05:00,XOMA,neutral
1389971.0,"XOMA Reports Q3 EPS $1.98 vs $(2.08) In Same Qtr. Last Year, Sales $36.183M vs $635K YoY",2017-11-06 16:11:00-05:00,XOMA,neutral
1389972.0,"H.C. Wainwright Assumes XOMA at Buy, Announces price target $38.00",2017-10-17 07:23:00-04:00,XOMA,neutral
1389973.0,"XOMA Reports Multiple New License Agreements for Proprietary Phage Display Libraries With Tizona Therapeutics, Inc., Torch Biosciences, Inc., and LakePharma",2017-10-04 09:16:00-04:00,XOMA,positive
1389974.0,XOMA Reports Earning Of $3M Milestone Payment Related To License Deal With Nanotherapeutics,2017-09-11 07:01:00-04:00,XOMA,neutral
1389975.0,Novartis Reports 6.6% Passive Stake in Xoma in 13G,2017-09-05 17:24:00-04:00,XOMA,positive
1389976.0,Mid-Afternoon Market Update: Dow Drops Over 200 Points; Insmed Shares Jump After Positive Results From Lung Disease Study,2017-09-05 14:31:00-04:00,XOMA,positive
1389977.0,12 Biggest Mid-Day Gainers For Tuesday,2017-09-05 12:35:00-04:00,XOMA,neutral
1389978.0,"Benzinga's Top Upgrades, Downgrades For September 5, 2017",2017-09-05 09:19:00-04:00,XOMA,positive
1389979.0,25 Stocks Moving In Tuesday's Pre-Market Session,2017-09-05 08:08:00-04:00,XOMA,neutral
1389980.0,Wedbush Upgrades XOMA to Outperform,2017-09-05 06:50:00-04:00,XOMA,neutral
1389981.0,Mid-Afternoon Market Update: GameStop Drops After Mixed Q2 Report; Pure Storage Shares Surge,2017-08-25 14:33:00-04:00,XOMA,positive
1389982.0,18 Biggest Mid-Day Gainers For Friday,2017-08-25 12:17:00-04:00,XOMA,neutral
1389983.0,Mid-Day Market Update: Adamas Pharma Climbs Following FDA Approval of GOCOVRI; Aceto Shares Plummet,2017-08-25 12:00:00-04:00,XOMA,positive
1389984.0,Mid-Morning Market Update: Markets Open Higher; Big Lots Profit Tops Estimates,2017-08-25 10:09:00-04:00,XOMA,positive
1389985.0,22 Stocks Moving In Friday's Pre-Market Session,2017-08-25 08:02:00-04:00,XOMA,neutral
1389986.0,"XOMA Getting Some Price Indications, But Still A Wide Spread On Bid/Ask: $11.35/$11.70, Respectively; Would Be Up Nearly 30% From Thurs. Close",2017-08-25 07:47:00-04:00,XOMA,positive
1389987.0,"XOMA Shares Open For Trade, But Have Not Yet Seen An Updated Last Price",2017-08-25 07:31:00-04:00,XOMA,positive
1389988.0,"XOMA Reports License Deals For Gevokizumab, IL-1 Beta IP Portfolio; Will Receive $31M In Upfront Payment, Including $5M Equity Investment",2017-08-25 07:01:00-04:00,XOMA,neutral
1389989.0,XOMA Shares Halted News Pending,2017-08-25 06:58:00-04:00,XOMA,positive
1389990.0,"XOMA Reports Q2 EPS $0.02 vs $(2.52) In Same Qtr. Last Year, Sales $10.89M vs $10.4M Est.",2017-08-08 16:33:00-04:00,XOMA,neutral
1389991.0,15 Biggest Mid-Day Gainers For Monday,2017-06-12 12:44:00-04:00,XOMA,neutral
1389992.0,"Benzinga's Top Upgrades, Downgrades For June 12, 2017",2017-06-12 09:25:00-04:00,XOMA,positive
1389993.0,H.C. Wainwright Initiates Coverage On XOMA with Buy Rating,2017-06-12 07:15:00-04:00,XOMA,neutral
1389994.0,XOMA Earns $10M Milestone Payment as Another of its Licensed Assets Advances into Clinical Development,2017-05-18 07:11:00-04:00,XOMA,positive
1389995.0,"XOMA Reports Q1 EPS $(2.37) May Not Compare To $(1.30) Est., Sales $260K vs $480K Est.",2017-05-09 17:22:00-04:00,XOMA,neutral
1389996.0,12 Biggest Mid-Day Losers For Monday,2017-04-24 13:23:00-04:00,XOMA,negative
1389997.0,Mid-Day Market Update: C R Bard Surges On Acquisition News; XOMA Shares Plunge,2017-04-24 13:16:00-04:00,XOMA,positive
1389998.0,Mid-Morning Market Update: Markets Open Higher; Halliburton Profit Tops Views,2017-04-24 10:05:00-04:00,XOMA,positive
1389999.0,25 Stocks Moving In Monday's Pre-Market Session,2017-04-24 08:20:00-04:00,XOMA,neutral
1390000.0,"XOMA Offers Phase 2 Proof-of-Concept Dstudy of Prolactin Inhibition: 'X213 shown to be safe and effective, demonstrating complete suppression of lactation in study participants'",2017-04-24 07:16:00-04:00,XOMA,positive
1390001.0,12 Biggest Mid-Day Gainers For Tuesday,2017-04-18 12:39:00-04:00,XOMA,neutral
1390002.0,25 Stocks Moving In Tuesday's Pre-Market Session,2017-04-18 08:35:00-04:00,XOMA,neutral
1390003.0,Xoma +15.2% Premarket @$7.48 After Co Announces  Positive Data from PTH1R Monoclonal Antibody Program,2017-04-18 08:21:00-04:00,XOMA,positive
1390004.0,Trump Stocks Get A Price Check,2017-03-27 10:08:00-04:00,XOMA,neutral
1390005.0,"Wedbush Reiterates Neutral On XOMA, Lowers Price Target To $9",2017-03-27 06:29:00-04:00,XOMA,negative
1390006.0,XOMA Reports Full Repayment of $6.5M In Hercules Technology Growth Capital Debt Obligation,2017-03-22 07:07:00-04:00,XOMA,neutral
1390007.0,"XOMA Reports Q4 EPS $(2.89) vs $(2.32) Est., Sales $524K vs $730K Est.",2017-03-16 07:06:00-04:00,XOMA,neutral
1390008.0,"Biotechnology Value Fund, L.P. Reports 19.99% Stake in Xoma in 13D",2017-02-21 17:10:00-05:00,XOMA,positive
1390009.0,Xoma Corp Trading Well Above Recent Offering Price But Below October Reverse Split Levels,2017-02-13 13:30:00-05:00,XOMA,positive
1390010.0,18 Biggest Mid-Day Gainers For Monday,2017-02-13 12:30:00-05:00,XOMA,neutral
1390011.0,XOMA Prices $25M Offering at $4.03/Share,2017-02-13 07:12:00-05:00,XOMA,neutral
1390012.0,XOMA Establishes Proof-of-Concept for 358 in Congenital Hyperinsulinism and Hypoglycemia Post-Bariatric Surgery,2017-01-31 16:10:00-05:00,XOMA,neutral
1390013.0,13 Emerging Biotechs With Catalysts In 2017,2017-01-03 14:22:00-05:00,XOMA,neutral
1390014.0,15 Biggest Mid-Day Gainers For Thursday,2016-12-22 12:35:00-05:00,XOMA,neutral
1390015.0,18 Stocks Moving In Thursday's Pre-Market Session,2016-12-22 08:31:00-05:00,XOMA,neutral
1390016.0,"XOMA Announces Sale Of Royalty Streams To HealthCare Royalty Partners For $18M Up Front, $4M In Milestone Payments",2016-12-21 17:01:00-05:00,XOMA,neutral
1390017.0,XOMA Challenged With A 'Major Financing Overhang',2016-11-15 10:39:00-05:00,XOMA,negative
1390018.0,Wedbush Downgrades XOMA Corporation - Common Stock to Neutral,2016-11-14 06:38:00-05:00,XOMA,neutral
1390019.0,"XOMA Reports Q3 EPS $(2.08) vs $(2.40) Est., Sales $635K vs $1.16M Est.",2016-11-09 09:01:00-05:00,XOMA,neutral
1390020.0,"7 Stocks That Rallied Four Days, Then Sold Off Yesterday",2016-11-01 10:03:00-04:00,XOMA,neutral
1390021.0,15 Biggest Mid-Day Losers For Wednesday,2016-10-19 12:36:00-04:00,XOMA,negative
1390022.0,XOMA Reports Significant Step Toward Initiating Pediatric Phase 2 Clinical Study for XOMA 358 in Children with Congenital Hyperinsulinism,2016-10-19 09:00:00-04:00,XOMA,positive
1390023.0,XOMA Announces Reverse Stock Split Of 1-For -20 Monday Oct. 17 After-Hours,2016-10-14 16:10:00-04:00,XOMA,neutral
1390024.0,"XOMA Reports Q2 EPS $(0.13) vs. Est. $(0.12), Rev. $443K vs. Est. $900K",2016-08-03 16:26:00-04:00,XOMA,neutral
1390025.0,UPDATE: XOMA Receives Orphan Drug Designation in the European Union for XOMA 358 for Treatment of Congenital Hyperinsulinism,2016-07-20 09:01:00-04:00,XOMA,neutral
1390026.0,XOMA Reports Received Orphan Drug Designation in EU for XOMA 358 for Treatment Congenital Hyperinsulinism,2016-07-20 09:00:00-04:00,XOMA,neutral
1390027.0,XOMA Shares Seeing Volume Since $0.48 Level Was Breached to the Upside; Stock Up ~10% for Session,2016-06-29 11:58:00-04:00,XOMA,positive
1390028.0,XOMA Reports Initiation of Phase 2 PoC Study of XOMA 213,2016-06-28 09:08:00-04:00,XOMA,neutral
1390029.0,"XOMA Reports Q1 EPS $(0.07) vs $(0.12) Est., Sales $3.962M vs $870K Est.",2016-05-04 16:54:00-04:00,XOMA,neutral
1390030.0,XOMA Starts XOMA 358 Proof-of-Concept Study in Patients with Hypoglycemia Post Gastric Bypass Surgery,2016-04-27 09:02:00-04:00,XOMA,neutral
1390031.0,Xoma Effected In Connection With Obtaining Regulatory Approval To Transfer Contract To Nanotherapeutics-Reuters,2016-03-22 16:10:00-04:00,XOMA,positive
1390032.0,Xoma Receives Delisting Notice,2016-03-18 16:10:00-04:00,XOMA,neutral
1390033.0,"Xoma Reports Q4 EPS $0.21 vs. Est. $(0.15), rev. $48.183M vs. Est. $4.01M",2016-03-09 16:19:00-05:00,XOMA,neutral
1390034.0,"Earnings Scheduled For March 9, 2016",2016-03-09 04:07:00-05:00,XOMA,neutral
1390035.0,>>  Option Alert: XOMA Mar16 1.0 Calls Sweep: 739 @  ASK  $0.10: 1965 traded vs 2010 OI:  Earnings 3/9 After Close  $0.89 Ref,2016-03-07 10:58:00-05:00,XOMA,positive
1390036.0,Every Biotech Catalyst Wedbush Is Watching In 2016,2016-01-02 20:20:00-05:00,XOMA,neutral
1390037.0,"Xoma +9% After-Hours @ $1.46 Following Announcement of Settlement, License Agreement With Pfizer",2015-12-09 17:12:00-05:00,XOMA,positive
1390038.0,"Xoma Says On December 3, Co, As Successor-In-Interest Of Xoma Ireland Ltd, Pfizer Entered into Settlement, Amended License Agreement; Xoma Granted Rights to Patented Bacterial Cell Expression Technology For Upfront Payment By Pfizer Of $3.8M",2015-12-09 17:09:00-05:00,XOMA,positive
1390039.0,"Wedbush's Moussatos Offers Probabilities for Upcoming Catalysts in Emerging Pharma Sector Heading Into '16: Discusses 14 Cos., Including BioMarin, Intercept, Regulus, Relypsa, Vitae, Xoma",2015-12-07 13:07:00-05:00,XOMA,neutral
1390040.0,"Wedbush Reiterates Outperform Rating, $6 Target on Xoma Following News Co. Licensed XMetA for Diabetes to Novo Nordisk",2015-12-02 06:59:00-05:00,XOMA,neutral
1390041.0,Morning Market Gainers,2015-12-01 09:43:00-05:00,XOMA,neutral
1390042.0,"UPDATE: Xoma Will Receive $5M Upfront Payment, Deal Includes Up to $290M in Added Potential Milestone Payments",2015-12-01 08:32:00-05:00,XOMA,neutral
1390043.0,XOMA Reports Licensing Deal with  Novo Nordisk for XMetA Program in Diabetes,2015-12-01 08:31:00-05:00,XOMA,neutral
1390044.0,Morning Market Losers,2015-11-06 09:53:00-05:00,XOMA,negative
1390045.0,"XOMA Reports Q3 Sales $2.1M vs $3.6M Est., Earnings $0.00 vs $(0.16) Est.",2015-11-05 16:29:00-05:00,XOMA,neutral
1390046.0,SOMA To Sell Manufacturing Facilities To Agenus,2015-11-05 16:11:00-05:00,XOMA,neutral
1390047.0,"Analyst: No Catalyst For Big Move In XOMA, Could Be Traders Bottom Feeding Stock",2015-11-03 15:51:00-05:00,XOMA,negative
1390048.0,"BZ NOTE: Wedbush's Dr. Liana Moussatos Has An Outperform Rating Of $6/Share, Mentions That There Is No Catalyst For Today's Move; Sees FY16 Potential",2015-11-03 14:05:00-05:00,XOMA,neutral
1390049.0,"Wedbush Analyst Dr. Liana Moussatos Sees No Near-Term Catalysts That Would Drive XOMA Shares Higher Today, Said Could Be Traders Bottom Feeding Stock; Need FY16 Horizon For Stock",2015-11-03 13:57:00-05:00,XOMA,neutral
1390050.0,"XOMA Shares Trading Up 30%, Benzinga Technician Highlights Heavy Volume and Technical Breakout; RBC Analyst Adnan Butt Confirms There's No News Or Fundamental Change In Company, Says Someone Is Just Buying Heavy Volume",2015-11-03 13:45:00-05:00,XOMA,neutral
1390051.0,Wedbush See 470% Upside At Xoma,2015-10-26 14:27:00-04:00,XOMA,neutral
1390052.0,"Wedbush's Moussatos Reiterates Outperform Rating, $6 Price Target on Shares of Xoma; BZ NOTE: Target Represents Potential Upside ~450% from XOMA Last Trade at $1.09",2015-10-26 12:42:00-04:00,XOMA,positive
1390053.0,Xoma +11% Premarket Following Announcement of Licensing Deal With Novartis,2015-10-21 07:44:00-04:00,XOMA,neutral
1390054.0,Morning Market Gainers,2015-10-01 09:43:00-04:00,XOMA,neutral
1390055.0,Benzinga's Top #PreMarket Gainers,2015-10-01 08:23:00-04:00,XOMA,positive
1390056.0,Xoma +86% Premarket After Resumption of Trading,2015-10-01 08:11:00-04:00,XOMA,neutral
1390057.0,XOMA Shares to Resume Trade at 8 a.m. EDT,2015-10-01 07:58:00-04:00,XOMA,positive
1390058.0,"Xoma To Receive $37M Upfront From Novartis And Is Eligible For $480M In Development, Commercial, And Regulatory Milestones",2015-10-01 07:31:00-04:00,XOMA,neutral
1390059.0,UPDATE: XOMA Announces Development and Commercialization Agreement,2015-10-01 07:31:00-04:00,XOMA,positive
1390060.0,XOMA Announces Development and Commercialization Agreement for First-in-Class Anti-TGF-beta Antibody Program in Immuno-Oncology,2015-10-01 07:30:00-04:00,XOMA,positive
1390061.0,XOMA Corp Halted News Pending,2015-10-01 07:25:00-04:00,XOMA,neutral
1390062.0,10% Annual Alpha? Why Pair Trades Make Sense When The Market Is Volatile,2015-09-14 13:31:00-04:00,XOMA,neutral
1390063.0,Xoma Says It Will Cut 30% of Workforce to Reduce Expenses,2015-08-25 06:07:00-04:00,XOMA,negative
1390064.0,"Xoma Reports Q2 Loss of $0.02/Share vs Loss of $0.18/Share Est., Sales $2.5M vs $4.4M Est.",2015-08-06 16:03:00-04:00,XOMA,negative
1390065.0,"Jefferies Downgrades XOMA, Slashes Price Target After Significantly Altering Model",2015-07-23 08:32:00-04:00,XOMA,negative
1390066.0,Jefferies Downgrades XOMA to Hold,2015-07-23 07:49:00-04:00,XOMA,neutral
1390067.0,"Market Update: Wednesday's Mid-Day Movers: U.S., Asian Markets Slow; Apple, Microsoft, Chipotle, IBM And More",2015-07-22 14:29:00-04:00,XOMA,neutral
1390068.0,Disappointing Drug News Sends Biogen And XOMA Shares Down,2015-07-22 10:34:00-04:00,XOMA,negative
1390069.0,Stocks Hitting 52-Week Lows,2015-07-22 10:23:00-04:00,XOMA,negative
1390070.0,Morning Market Losers,2015-07-22 09:58:00-04:00,XOMA,negative
1390071.0,"Xoma Shares Resume Trading, Fall 72% Following Failed Phase 3 Eyeguard-B Study",2015-07-22 08:32:00-04:00,XOMA,negative
1390072.0,Benzinga's Top #PreMarket Losers,2015-07-22 08:28:00-04:00,XOMA,negative
1390073.0,Xoma Shares Traded as Low as $3.05 Following Results of Phase 3 Eyeguard-B Study,2015-07-22 08:12:00-04:00,XOMA,neutral
1390074.0,Nasdaq Says XOMA Traded After 8:00AM ET on Bats Exchange; Nasdaq Contacted Bats Regarding the Matter,2015-07-22 08:10:00-04:00,XOMA,neutral
1390075.0,Shares of XOMA to Resume Trade at 8:30 a.m. EDT,2015-07-22 08:03:00-04:00,XOMA,positive
1390076.0,Xoma Offers Results from Phase 3 EYEGUARD(TM)-B Study: Appeared Well Tolerated in Trial But Did Not Meet Primary Endpoint,2015-07-22 08:01:00-04:00,XOMA,positive
1390077.0,Shares of Xoma Halted News Pending,2015-07-22 07:57:00-04:00,XOMA,positive
1390078.0,New Alzheimer's Trials Could Produce The Most Important Drugs In History,2015-07-21 15:14:00-04:00,XOMA,positive
1390079.0,Xoma Corp Shares Spiking Higher,2015-07-09 11:37:00-04:00,XOMA,positive
1390080.0,Option Alert: Xoma Jul $4.5 Call Sweep; 1035 Contracts @Ask @$0.50; Now $3.74,2015-07-08 14:43:00-04:00,XOMA,positive
1390081.0,How Wedbush's Liana Moussatos Is Trading These Biopharma Stocks,2015-07-06 15:41:00-04:00,XOMA,neutral
1390083.0,Benzinga's Top Downgrades,2015-06-29 10:01:00-04:00,XOMA,positive
1390084.0,Susquehanna Downgrades XOMA To  Neutral,2015-06-29 08:52:00-04:00,XOMA,neutral
1390085.0,Susquehanna Downgrades XOMA to Neutral,2015-06-29 07:23:00-04:00,XOMA,neutral
1390087.0,Mid-Afternoon Market Update: Dow Surges Over 100 Points; Avalanche Biotechnologies Shares Dip Following Mixed AVA-101 Data,2015-06-16 15:27:00-04:00,XOMA,positive
1390088.0,Mid-Day Market Update: Coty Jumps On Report of Deal With P&G; Tahoe Resources Shares Drop,2015-06-16 13:25:00-04:00,XOMA,neutral
1390089.0,Mid-Morning Market Update: Markets Rise; FactSet Profit Beats Estimates,2015-06-16 10:49:00-04:00,XOMA,positive
1390090.0,XOMA Receives Orphan Drug Designation for XOMA 358 From U.S. FDA for Treatment of Congenital Hyperinsulinism (HI),2015-06-16 09:02:00-04:00,XOMA,neutral
1390091.0,"UPDATE: Wedbush's Liana Moussatos Sees 'The Last Exacerbation in EYEGUARD-B' Has Occured for Xoma, Expecting 'Positive Topline Results in July'",2015-05-28 12:20:00-04:00,XOMA,positive
1390092.0,"Hearing Wedbush Reiterates Buy, $17 PT on Xoma",2015-05-28 12:16:00-04:00,XOMA,neutral
1390093.0,Option Alert: Xoma Sep $4 Call; 1000 Contract Trade @$1.10,2015-05-28 11:10:00-04:00,XOMA,positive
1390094.0,XOMA Reports Phase 3 EYEGUARD-B Study Reaches Target Exacerbation Event,2015-05-28 08:31:00-04:00,XOMA,positive
1390095.0,Morning Market Gainers,2015-05-08 09:49:00-04:00,XOMA,neutral
1390096.0,Benzinga's Top #PreMarket Gainers,2015-05-08 08:21:00-04:00,XOMA,positive
1390097.0,Credit Suisse Analysts Assume Coverage On 10 Biotech Stocks,2015-05-06 17:41:00-04:00,XOMA,positive
1390098.0,"Credit Suisse Assumes XOMA at Neutral, Announces $5.00 PT",2015-05-05 17:07:00-04:00,XOMA,positive
1390099.0,"Pandora, Sohu.com, Infinity Pharmaceuticals Lead Friday's After-Hours Movers",2015-04-10 19:01:00-04:00,XOMA,neutral
1390100.0,Servier Initiates Phase 2 Study of Gevokizumab in Patients With Diabetic Nephropathy,2015-04-01 08:04:00-04:00,XOMA,neutral
1390101.0,Wedbush Expects Cash Runway To Last Through Anticipated Catalysts In 2015 For XOMA,2015-03-13 07:09:00-04:00,XOMA,neutral
1390102.0,Ladenburg Thalmann Upgrades XOMA to Buy,2015-03-12 14:25:00-04:00,XOMA,neutral
1390103.0,Xoma Spike Higher,2015-03-12 13:20:00-04:00,XOMA,neutral
1390104.0,Credit Suisse Sees All Eyes On Eyeguard B Data for XOMA,2015-03-12 09:02:00-04:00,XOMA,positive
1390105.0,"Xoma Reports Q2 Loss of $0.12/Share vs Loss of $0.15/Share Est., Sales $4.34M vs $10.7M Est.",2015-03-11 16:03:00-04:00,XOMA,negative
1390106.0,XOMA Shares Spike Higher Following Wedbush Price Target Increase,2015-03-09 16:53:00-04:00,XOMA,positive
1390107.0,Xoma Shares Spike Higher as Wedbush Raises PT to $17.00,2015-03-09 14:58:00-04:00,XOMA,positive
1390108.0,XOMA Presents Positive Phase 1 XOMA 358 Data at the ENDO 2015,2015-03-07 16:07:00-05:00,XOMA,positive
1390109.0,XOMA Will Present XOMA 358 Phase 1 Data at ENDO 2015,2015-03-05 16:22:00-05:00,XOMA,neutral
1390110.0,US Stock Futures Edge Lower Ahead Of Auto Sales,2015-03-03 07:53:00-05:00,XOMA,negative
1390111.0,XOMA Announces Retirement of Fred Kurland and Appointment of Thomas Burns as Chief Financial Officer,2015-03-03 07:09:00-05:00,XOMA,neutral
1390112.0,Morning Market Gainers,2015-03-02 09:45:00-05:00,XOMA,neutral
1390113.0,Benzinga's Top #PreMarket Gainers,2015-03-02 08:11:00-05:00,XOMA,positive
1390114.0,Xoma At Key Technical Level,2014-12-30 08:33:00-05:00,XOMA,neutral
1390115.0,XOMA Announces Pricing Of $40.0M Registered Offering Of Common Stock And Warrants,2014-12-09 09:02:00-05:00,XOMA,neutral
1390116.0,Here's The Latest Biotech Breakout,2014-11-26 12:01:00-05:00,XOMA,neutral
1390117.0,XOMA Corp Volatile Amid Differing Analyst Reports,2014-11-10 11:45:00-05:00,XOMA,neutral
1390118.0,"Ladenburg Thalmann Downgrades XOMA Corporation to Neutral, Removes $8.00 PT",2014-11-10 09:31:00-05:00,XOMA,neutral
1390119.0,"XOMA Corporation Reports Q3 EPS of $(0.17), Inline; Revenue of $5.10M vs $6.96M Est",2014-11-06 16:04:00-05:00,XOMA,neutral
1390120.0,XOMA Initiates Pivotal Phase 3 Gevokizumab Study ,2014-11-04 09:18:00-05:00,XOMA,neutral
1390121.0,XOMA Launches XOMA 358 Clinical Development,2014-10-09 09:22:00-04:00,XOMA,neutral
1390122.0,"XOMA Licensing Manufacturing Tech To Texas A&M, No Terms Disclosed",2014-10-06 13:05:00-04:00,XOMA,negative
1390123.0,XOMA Initiates U.S. Clinical Trial of Gevokizumab In Patients With Behcet's Disease Uveitis - EYEGUARD - US,2014-09-30 16:06:00-04:00,XOMA,neutral
1390124.0,Xoma Spikes Higher,2014-09-04 11:53:00-04:00,XOMA,neutral
1390125.0,"Option Alert: Xoma Mar $5 Call; 2,000 Contracts Traded vs 95 OI; Currently $4.30",2014-08-12 09:58:00-04:00,XOMA,positive
1390126.0,MLV & Co Has Positive Outlook On XOMA,2014-08-08 10:00:00-04:00,XOMA,positive
1390127.0,XOMA Corporation Reports Q2 EPS of $(0.17) vs $(0.21) Est; Revenue of $5.97M vs $5.32M Est,2014-08-07 16:06:00-04:00,XOMA,neutral
1390128.0,XOMA Corporation Reports Q1 EPS of $(0.23) vs $(0.17) Est; Revenue of $3.41M vs $7.40M Est,2014-05-07 16:18:00-04:00,XOMA,neutral
1390129.0,"XOMA to Announce Q1 2014 Financial Results on May 7, 2014, After the Market Close",2014-04-30 13:27:00-04:00,XOMA,neutral
1390130.0,Morning Market Movers ,2014-04-29 09:43:00-04:00,XOMA,neutral
1390131.0,UPDATE: MLV & Co Upgrades XOMA on Valuation,2014-04-29 07:56:00-04:00,XOMA,neutral
1390132.0,"McNicoll Lewis Vlak Upgrades XOMA Corporation to Buy, Maintains $7.00 PT",2014-04-29 06:24:00-04:00,XOMA,neutral
1390133.0,XOMA Finalizes Plans for Gevokizumab Phase 3 Clinical Program in Pyoderma Gangrenosum ,2014-04-28 09:03:00-04:00,XOMA,neutral
1390134.0,"Option Alert: XOMA Jan $5 Call; 2,000 Contracts Trade between Bid and Ask @41.60; Currently $4.29",2014-04-23 15:00:00-04:00,XOMA,positive
1390135.0,"Option Alert: XOMA Sep $5 Call; 3,006 Contracts Traded vs 465 OI; Currently $4.08",2014-04-15 10:15:00-04:00,XOMA,positive
1390136.0,Benzinga's Top Downgrades,2014-03-11 08:35:00-04:00,XOMA,positive
1390137.0,UPDATE: MLV & Co Downgrades XOMA on Valuation/Sentiment,2014-03-11 08:14:00-04:00,XOMA,neutral
1390138.0,"McNicoll Lewis Valk Downgrades XOMA Corporation to Hold, Lowers PT to $7.00",2014-03-11 06:21:00-04:00,XOMA,negative
1390139.0,Market Wrap For March 5: Markets Calm Following Tuesday's Massive Rally,2014-03-05 16:40:00-05:00,XOMA,positive
1390140.0,Mid-Afternoon Market Update: FuelCell Energy Hangs on to Gains as Canadian Solar Shares Fall on Poor Report,2014-03-05 15:27:00-05:00,XOMA,positive
1390141.0,Mid-Day Market Update: Smith & Wesson Surges On Upbeat Results; XOMA Shares Drop,2014-03-05 13:19:00-05:00,XOMA,neutral
1390142.0,Ladenburg Thalmann Increases Target on XOMA from $6.50 to $10,2014-03-05 11:52:00-05:00,XOMA,neutral
1390143.0,Mid-Morning Market Update: Markets Mostly Flat; Brown-Forman Posts Higher Profit,2014-03-05 10:22:00-05:00,XOMA,positive
1390144.0,"Morning Lowers for Mar. 5, 2014: XOMA, USU, CSIQ, AUDC, RATE",2014-03-05 10:14:00-05:00,XOMA,negative
1390145.0,Benzinga's Top #PreMarket Losers,2014-03-05 08:13:00-05:00,XOMA,negative
1390146.0,Credit Suisse Downgrades XOMA Corporation to Neutral,2014-03-05 07:52:00-05:00,XOMA,positive
1390147.0,"XOMA Shares Have Resumed, Stock Now Trading Down ~18% to $7.72",2014-03-04 18:12:00-05:00,XOMA,positive
1390148.0,PREVIEW: XOMA to Resume Trading at 5:25 PM ET,2014-03-04 17:01:00-05:00,XOMA,neutral
1390149.0,XOMA Corporation Reports Q4 EPS of $(0.18) vs $(0.19) Est; Revenue of $12.53M vs $7.92M Est,2014-03-04 16:58:00-05:00,XOMA,neutral
1390150.0,"UPDATE: XOMA Offers Update on Gevokizumaba, Says Results Do Not Support Movement to Pivotal Development Trial",2014-03-04 16:42:00-05:00,XOMA,negative
1390151.0,"XOMA Offers Update on Gevokizumaba, Says Results Do Not Support Movement to Pivotal Development Trial",2014-03-04 16:37:00-05:00,XOMA,negative
1390152.0,XOMA Halted News Pending,2014-03-04 16:26:00-05:00,XOMA,neutral
1390153.0,"Morning Movers for Feb. 25, 2014: IMUC, MSO, ZU, CARA, VSI, TSLA, XOMA, BCRX Moving Higher, RP, ODP, VVUS, AINV, MGIC, ALSN Lower",2014-02-25 09:41:00-05:00,XOMA,negative
1390154.0,UPDATE: XOMA Receives FDA Orphan Drug Designation for Pyoderma Gangrenosum ,2014-02-24 21:13:00-05:00,XOMA,neutral
1390155.0,XOMA Receives FDA Orphan Status for Pyoderma Gangrenosum Drug,2014-02-24 15:02:00-05:00,XOMA,neutral
1390156.0,Stocks Hitting 52-Week Highs,2014-01-13 10:50:00-05:00,XOMA,neutral
1390157.0,"Jefferies Initiates Coverage on XOMA Corporation at Buy, Announces $11.00 PT",2014-01-09 08:10:00-05:00,XOMA,neutral
1390158.0,Benzinga's Top #PreMarket Losers,2014-01-02 08:20:00-05:00,XOMA,negative
1390159.0,XOMA Announces Closing of the Offering and Exercise of 1.425M Share Over Allotment Option,2013-12-18 16:04:00-05:00,XOMA,positive
1390160.0,XOMA Announces Pricing of 9.5M Shares at $5.25 per Share,2013-12-13 09:15:00-05:00,XOMA,positive
1390161.0,XOMA Prices 9.5M Share Offering at $5.25/Share,2013-12-13 09:15:00-05:00,XOMA,positive
1390162.0,Benzinga's Top #PreMarket Losers ,2013-12-13 08:38:00-05:00,XOMA,negative
1390163.0,Market Wrap For December 12: Dow Suffers Second Consecutive Day of Triple Point Loss,2013-12-12 16:41:00-05:00,XOMA,negative
1390164.0,XOMA Corporation Reports Q3 EPS of $(0.21) vs $(0.18) Est; Revenue of $6.31M vs $7.87M Est,2013-11-07 16:27:00-05:00,XOMA,neutral
1390165.0,Benzinga's Top #PreMarket Gainers,2013-10-31 08:13:00-04:00,XOMA,positive
1390166.0,Xoma Shares Rise 6% After-Hours on Encouraging Phase 2 Gevokizumab Results,2013-10-30 16:57:00-04:00,XOMA,positive
1390167.0,"XOMA Shares Quiet Following Results of Two Phase 2 Trials Showing Gevokizumab Program 'Very Encouraging,' 'Compelling'",2013-10-30 16:50:00-04:00,XOMA,positive
1390168.0,XOMA Files $150M Mixed Securities Shelf,2013-09-10 17:18:00-04:00,XOMA,positive
1390169.0,"XOMA Closes Offering, Reports Exercise of Over-Allotment Option, Sees Proceeds ~$29.3M",2013-08-23 12:13:00-04:00,XOMA,neutral
1390170.0,XOMA Prices 7.6M Shares at $3.62/Share,2013-08-20 08:31:00-04:00,XOMA,positive
1390171.0,UPDATE: Piper Jaffray Initiates XOMA at Overweight on 'Xciting Antibody Play',2013-08-13 08:40:00-04:00,XOMA,neutral
1390172.0,Benzinga's Top Initiations,2013-08-13 08:10:00-04:00,XOMA,positive
1390173.0,"Piper Jaffray Initiates Coverage on XOMA Corporation at Overweight, Announces $8.00 PT",2013-08-13 06:39:00-04:00,XOMA,negative
1390174.0,"Piper Jaffray Initiates Coverage on XOMA Corporation at Overweight, Announces $8.00 PT",2013-08-12 16:27:00-04:00,XOMA,negative
1390175.0,"Option Alert: XOMA October 5 Call; 6,523 Contracts Traded vs 2,166 Open Interest; Currently $4.61",2013-08-08 11:46:00-04:00,XOMA,positive
1390176.0,XOMA Corporation Reports Q2 EPS of $(0.21) vs $(0.19) Est; Revenue of $7.15M vs $9.30M Est,2013-08-07 16:13:00-04:00,XOMA,neutral
1390177.0,XOMA Completes Enrollment in Phase 2 Proof-of-Concept Gevokizumab Trial in Patients With Erosive Osteoarthritis of the Hand,2013-07-22 08:02:00-04:00,XOMA,positive
1390178.0,Benzinga's Top Pre-Market Gainers,2013-07-15 08:14:00-04:00,XOMA,positive
1390179.0,XOMA Transfers Perindopril Franchise Rights to Symplmed,2013-07-03 09:02:00-04:00,XOMA,neutral
1390180.0,XOMA to Get Equity Position in Symplmed,2013-07-03 09:01:00-04:00,XOMA,neutral
1390181.0,XOMA's Development Partner SERVIER Launches Proof-of-Concept Clinical Program for Gevokizumab,2013-06-25 09:06:00-04:00,XOMA,neutral
1390182.0,XOMA Begins Pilot Trial Evaluating Gevokizumab,2013-06-13 09:02:00-04:00,XOMA,neutral
1390183.0,UPDATE: Canaccord Genuity Upgrades XOMA to Buy on Increased Confidence,2013-05-09 10:11:00-04:00,XOMA,positive
1390184.0,Benzinga's Top Upgrades,2013-05-09 08:31:00-04:00,XOMA,positive
1390185.0,"Canaccord Genuity Upgrades XOMA Corporation to Buy, Raises PT to $8.00",2013-05-09 06:35:00-04:00,XOMA,neutral
1390186.0,XOMA Corporation Reports Q1 EPS of $(0.15) vs $(0.20) Est; Revenue of $9.45M vs $8.60M Est,2013-05-08 16:24:00-04:00,XOMA,neutral
1390187.0,XOMA Says Study Investigating Gevokizumab Opened for Enrollment,2013-04-10 08:05:00-04:00,XOMA,neutral
1390188.0," XOMA Shares Edge Higher Following New Buy Rating, $5 Target at Roth",2013-03-15 10:57:00-04:00,XOMA,positive
1390189.0,XOMA Corporation Reports Q4 EPS of $(0.18) vs $(0.26) Est,2013-03-12 16:15:00-04:00,XOMA,neutral
1390190.0,"Benzinga Market Primer: Tuesday, March 12",2013-03-12 06:49:00-04:00,XOMA,neutral
1390191.0,"Earnings Scheduled For March 12, 2013",2013-03-12 04:41:00-04:00,XOMA,neutral
1390192.0,Benzinga's Top Pre-Market Losers,2013-02-04 08:22:00-05:00,XOMA,negative
1390193.0,UPDATE: Wedbush Raises PT to $5 on Xoma on Gevokizumab Initial Efficacy  ,2013-01-07 14:14:00-05:00,XOMA,neutral
1390194.0,"Wedbush Maintains Outperform on XOMA Corporation, Raises PT to $5.00",2013-01-07 13:04:00-05:00,XOMA,neutral
1390195.0,XOMA Offers Encouraging Interim Results from Gevokizumab Phase 2 Study,2013-01-07 08:03:00-05:00,XOMA,positive
1390196.0,XOMA Says Sevier Initiated Proof-of-Concept Gevokizumab Study for Acute Coronary Syndrome Patients,2012-11-29 08:25:00-05:00,XOMA,neutral
1390197.0,UPDATE: Credit Suisse Initiates XOMA Corporation at Outperform on Upside Potential  ,2012-11-13 13:44:00-05:00,XOMA,positive
1390198.0,"Credit Suisse Initiates Coverage on XOMA New at Outperform, Announces PT of $4",2012-11-12 16:25:00-05:00,XOMA,positive
1390199.0,XOMA Prices 13.33M Shares at $3 Each,2012-10-24 08:59:00-04:00,XOMA,positive
1390200.0,XOMA Announces Servier Has Initiated Phase 3 Gevokizumab Trial in Patients With Behcet's Uveitis,2012-09-27 13:15:00-04:00,XOMA,neutral
1390201.0,UPDATE: XOMA Receives Orphan Drug Designation From FDA for Gevokizumab,2012-08-22 16:55:00-04:00,XOMA,neutral
1390202.0,Xoma Granted FDA Orphan Drug Status for Gevokizumab,2012-08-22 12:41:00-04:00,XOMA,positive
1390203.0,XOMA New Reports Q2 EPS $-0.24 vs $-0.22 Est; Revenues $9.28M vs $11.81M Est,2012-08-07 16:16:00-04:00,XOMA,neutral
1390204.0,CMC Biologics Acquires XOMA's Bay Area Manufacturing Facility; Terms Not Disclosed,2012-07-31 08:04:00-04:00,XOMA,neutral
1390205.0,Oncobiologics Announces Agreement To Utilize XOMA's Fully Human Antibody Libraries For Discovery Platform,2012-07-30 10:08:00-04:00,XOMA,positive
1390206.0,3 New Bets by a Biotech Hedge Fund,2012-07-13 17:32:00-04:00,XOMA,neutral
1390207.0,Benzinga's Top Initiations,2012-06-28 07:51:00-04:00,XOMA,positive
1390208.0,XOMA Initiates Phase 3 Gevokizumab Trial in Patients With Non-Infectious Uveitis and Phase 2 Gevokizumab Trial in Patients With Erosive Osteoarthritis ,2012-06-27 08:03:00-04:00,XOMA,neutral
1390209.0,Cowen Initiates Coverage on XOMA New at Outperform,2012-05-14 07:49:00-04:00,XOMA,neutral
1390210.0,"Ladenburg Thalmann Maintains XOMA New at Buy, Raises PT from $4.5 to $5.5",2012-05-09 07:40:00-04:00,XOMA,neutral
1390211.0,"Stock Watch List for Wednesday May 9, 2012",2012-05-08 17:28:00-04:00,XOMA,neutral
1390212.0,Xoma Moves Higher after Business Times Article States Company is Takeover Target,2012-04-30 07:56:00-04:00,XOMA,neutral
1390213.0,XOMA Spiking Higher on Heavy Volume; Currently at $2.67,2012-03-29 13:13:00-04:00,XOMA,neutral
1390214.0,UPDATE: Ladenburg Thalmann Lowers XOMA's PT,2012-03-20 14:23:00-04:00,XOMA,negative
1390215.0,"Ladenburg Thalmann Maintains XOMA at Buy, Lowers PT from $9 to $4.5",2012-03-20 12:49:00-04:00,XOMA,negative
1390216.0,XOMA Announces Pricing of $39.2 Million Public Offering of Common Stock and Warrants,2012-03-06 09:00:00-05:00,XOMA,neutral
1390217.0,Earnings Scheduled For March 6,2012-03-06 03:58:00-05:00,XOMA,neutral
1390218.0,XOMA Announces Proposed Public Offering of Common Stock and Warrants ,2012-03-05 16:02:00-05:00,XOMA,neutral
1390219.0,Ladenburg Thalmann Xoma Adds Servier's Perindopril Franchise to U.S. Pipeline  ,2012-01-18 10:54:00-05:00,XOMA,neutral
1390220.0,"End-of-Day Market Summary for January 17, 2012",2012-01-17 16:16:00-05:00,XOMA,neutral
1390221.0,XOMA Acquires U.S. Rights to Perindopril Franchise and Establishes Commercial Operations  ,2012-01-17 16:06:00-05:00,XOMA,neutral
1390222.0,Xoma Shares Down After Job Cuts and One Time Charges Announced,2012-01-13 13:05:00-05:00,XOMA,negative
1390223.0,"Benzinga's Microcap Movers for Thursday January 5, 2012",2012-01-05 20:24:00-05:00,XOMA,neutral
1390224.0,XOMA Resumes Trading,2012-01-05 13:10:00-05:00,XOMA,neutral
1390225.0,PREVIEW: XOMA to Resume Trading at 1:10pm,2012-01-05 12:55:00-05:00,XOMA,neutral
1390226.0,XOMA Streamlines Operations to Invest in Value-Creating Activities; Cuts 34% of Workforce,2012-01-05 12:45:00-05:00,XOMA,negative
1390227.0,XOMA Corporation New CEO Says Company Expects to Initiate Global Gevokizumab Phase 3 Program in Q2 of 2012,2012-01-05 12:38:00-05:00,XOMA,neutral
1390228.0,XOMA Appoints John Varian as Chief Executive Officer ,2012-01-05 12:30:00-05:00,XOMA,neutral
1390229.0,XOMA Corporation Halted for Pending News,2012-01-05 12:25:00-05:00,XOMA,neutral
1390230.0,XOMA Secures $10 Million Term Loan,2012-01-03 08:01:00-05:00,XOMA,positive
1390231.0,XOMA Will Move Its Corporate Domicile to Delaware ,2011-12-30 16:05:00-05:00,XOMA,neutral
1390232.0,XOMA Initiates Gevokizumab Phase 2 Study for Moderate to Severe Acne Vulgaris ,2011-12-21 08:05:00-05:00,XOMA,negative
1390233.0,XOMA Expands Gevokizumab (XOMA 052) Program  ,2011-11-09 16:08:00-05:00,XOMA,positive
1390234.0,XOMA Secures Federal Contract to Expand Its Next-Generation Human Botulism Antitoxin Portfolio,2011-10-03 08:05:00-04:00,XOMA,positive
1390235.0,"UPDATE: XOMA Names Varian Interim CEO, Van Ness Chairman",2011-08-31 16:36:00-04:00,XOMA,neutral
1390236.0,XOMA CEO Engle Resigns,2011-08-31 16:36:00-04:00,XOMA,negative
1390237.0,Xoma Spokesperson: 'We are not aware of any announcements that would account for price movement in stock'; Xoma Shares Rose Over 50% Today,2011-08-12 13:57:00-04:00,XOMA,positive
1390238.0,Top Percentage Gainers and Losers as of 2pm 6/28/11,2011-06-28 14:00:00-04:00,XOMA,negative
1390239.0,Hearing XOMAs Recent Spike Higher Attributed To Announcement Of Preclinical Data For Its Antibody Treatment For Type2 Diabetes,2011-06-27 11:11:00-04:00,XOMA,neutral
1390240.0,XOMA Spiking Higher on Heavy Volume,2011-06-27 10:55:00-04:00,XOMA,neutral
1390241.0,XOMA Ltd Spiking Higher on Heavy Volume,2011-06-27 10:55:00-04:00,XOMA,neutral
1390242.0,Stocks to Watch for 6/21/11: Fresh 52 Week Highs and Lows,2011-06-21 04:09:00-04:00,XOMA,positive
1390243.0,XOMA Announces Phase 2a Six-Month Top Line Trial Results Support Safety and Biological Activity ,2011-06-08 16:16:00-04:00,XOMA,positive
1390244.0,XOMA 3AB Enters Phase 1 Clinical Testing  ,2011-05-03 08:50:00-04:00,XOMA,neutral
1390245.0,XOMA Limited Up Nearly 4% (XOMA),2011-04-25 12:57:00-04:00,XOMA,negative
1390246.0,"Morning Top Percentage Gainers And Losers (XNPT, GSK, XOMA, BKE, TPCG, BBBY, QXM, RT, NLST, MDRX, BID) ",2011-04-07 10:28:00-04:00,XOMA,negative
1390247.0,"Benzinga's Top Pre-Market NASDAQ Losers (RIMM, PANL, NFLX, XOMA)",2011-03-25 08:14:00-04:00,XOMA,negative
1390248.0,"Morning Market Losers (XOMA, DGW, KFS, INS)",2011-03-23 09:55:00-04:00,XOMA,negative
1390249.0,"Benzinga's Top Pre-Market NASDAQ Losers (XOMA, VECO, CREE, AIXG)",2011-03-23 08:15:00-04:00,XOMA,negative
1390250.0,Wedbush Reiterates Buy Rating On XOMA,2011-03-23 07:42:00-04:00,XOMA,neutral
1390251.0,XOMA Trading Significantly Lower Pre-Market (XOMA),2011-03-23 07:23:00-04:00,XOMA,negative
1390252.0,XOMA Resumes; Drops 30% On Phase 2 Data (XOMA),2011-03-22 16:51:00-04:00,XOMA,neutral
1390253.0,Trading Resumes: XOMA,2011-03-22 16:50:00-04:00,XOMA,neutral
1390254.0,XOMA Trading to Resume at 4.50 pm,2011-03-22 16:26:00-04:00,XOMA,neutral
1390255.0,"XOMA 052 Phase 2b Top Line Results: Glucose Control Not Demonstrated, Positive Anti-inflammatory Effect, Cardiovascular Biomarker and Lipid Improvement and Safety Confirmed  ",2011-03-22 16:21:00-04:00,XOMA,positive
1390256.0,"Trading Halted: XOMA, News Pending",2011-03-22 16:19:00-04:00,XOMA,neutral
1390257.0,Trade Ideas for the Week of March 14,2011-03-11 18:05:00-05:00,XOMA,neutral
1390258.0,Options Brief: XOMA Ltd. (XOMA),2011-03-11 12:13:00-05:00,XOMA,neutral
1390259.0,XOMA Limited Posts EPS of $(0.84) Vs Consensus of $(0.82),2011-03-10 16:10:00-05:00,XOMA,negative
1390260.0,"Benzinga's Top Downgrades (MOS, CLR, XOMA, CSA)",2011-03-09 08:21:00-05:00,XOMA,positive
1390261.0,Canaccord Downs XOMA To Hold,2011-03-09 06:46:00-05:00,XOMA,neutral
1390262.0,XOMA Falls 13.7% (XOMA),2011-01-07 15:54:00-05:00,XOMA,neutral
1390263.0,"Benzinga's Top Pre-Market NASDAQ Losers (XOMA, XRTX, SVNT, ERIC)",2011-01-07 08:34:00-05:00,XOMA,negative
1390264.0,Biotech Stock Mailbag: Best Stocks to Watch in '11,2011-01-07 07:00:00-05:00,XOMA,positive
1390265.0,Xoma Partners Servier for XOMA 052 - Analyst Blog,2011-01-07 02:03:00-05:00,XOMA,neutral
1390266.0,Xoma Partners Servier for XOMA 052 - Analyst Blog,2011-01-06 13:00:00-05:00,XOMA,neutral
1390267.0,Xoma Partners Servier for XOMA 052 - Analyst Blog,2011-01-06 12:30:00-05:00,XOMA,neutral
1390268.0,Xoma Partners Servier for XOMA 052 - Analyst Blog,2011-01-06 12:30:00-05:00,XOMA,neutral
1390269.0,"Benzinga's Top Pre-Market NASDAQ Losers (LOGI, XOMA, ASML, HBAN)",2011-01-05 08:25:00-05:00,XOMA,negative
1390270.0,XOMA Surges 40.4% After Deal With Servier (XOMA),2011-01-04 15:59:00-05:00,XOMA,neutral
1390271.0,"Morning Market Movers (USAT, RPC, XOMA, GCFB)",2011-01-04 10:01:00-05:00,XOMA,neutral
1390272.0,XOMA Trading Up 16.98% Pre-Market,2011-01-04 09:10:00-05:00,XOMA,neutral
1390273.0,XOMA and Servier Sign Development Agreement for XOMA 052  ,2011-01-04 07:56:00-05:00,XOMA,positive
1390274.0,Xoma: Key Diabetes Drug Study Preview,2011-01-03 19:03:00-05:00,XOMA,neutral
1390275.0,"XOMA Shares Climb 8.6% (XOMA, NVG, MRK)",2010-12-30 14:23:00-05:00,XOMA,positive
1390276.0,"Benzinga's Top Pre-Market NASDAQ Gainers (XING, VISN, OSN, XOMA)",2010-12-30 08:22:00-05:00,XOMA,positive
1390277.0,"Benzinga's Top Pre-Market NASDAQ Gainers (CRNT, AUDC, XOMA, BIDU)",2010-12-29 08:15:00-05:00,XOMA,positive
1390278.0,"Mid-Day Market Losers (XOMA, DARA, BPAX, BASI)",2010-12-28 12:12:00-05:00,XOMA,negative
1390279.0,"Cisco, Netflix: Premarket Trading",2010-12-28 07:31:00-05:00,XOMA,neutral
1390280.0,"1 Huge Winner, 2 Big Losers (DRYS, XOMA, REPRX)",2010-12-27 14:10:00-05:00,XOMA,positive
1390281.0,XOMA Dropping In Pre-Market (XOMA),2010-12-27 08:14:00-05:00,XOMA,neutral
1390282.0,XOMA Ends Day Up 59% (XOMA),2010-12-23 16:25:00-05:00,XOMA,neutral
1390283.0,"NASDAQ Morning Percentage Gainers;SNIC,XOMA,SBAY,AIXG,OTIV",2010-12-23 11:16:00-05:00,XOMA,neutral
1390284.0,XOMA Ltd Soars 30% (XOMA),2010-12-23 11:09:00-05:00,XOMA,neutral
1390285.0,XOMA Down Slightly After Huge Run Yesterday (XOMA),2010-12-22 08:50:00-05:00,XOMA,positive
1390286.0,"Morning Movers on NASDAQ; LCRD, MATK, XOMA, AMED, TBAC",2010-12-21 15:24:00-05:00,XOMA,neutral
1390287.0,Worst Biotech CEO of 2010 Is...,2010-12-09 07:01:00-05:00,XOMA,negative
1390288.0,Vote for the Worst Biotech CEO of 2010,2010-12-01 07:00:00-05:00,XOMA,negative
1390289.0,"Top Narrow Based Indexes For August 4 (XJT, EMMS, XOMA)",2010-08-04 14:20:00-04:00,XOMA,positive
1390290.0,"Top Narrow Based Indexes For August 4 (XJT, EMMS, XOMA)",2010-08-04 14:13:00-04:00,XOMA,positive
1390291.0,XOMA Ltd. (NASDAQ:XOMA) Announces $1 Million Milestone Payment From Takeda Pharmaceutical,2010-04-15 09:31:00-04:00,XOMA,neutral
1390292.0,"McNicoll, Lewis & Vlak LLC Maintains Buy Rating On XOMA Limited (XOMA)",2010-04-14 11:48:00-04:00,XOMA,negative
1390293.0,"XOMA Receives Key Patents, Stock Soars",2010-04-14 08:26:00-04:00,XOMA,neutral
1390294.0,XOMA Ltd. (XOMA) Shares Surge 17% On Patent News,2010-04-13 10:19:00-04:00,XOMA,positive
1390295.0,How Will Obama-Care Play Into The Markets And ETFs?,2010-03-21 21:50:00-04:00,XOMA,positive
